Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NEO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Fraud / investigation
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Civil Money Penalty (new) — Company paid $9.8M to settle DOJ investigation into consulting services compliance with federal healthcare fraud, waste and abuse laws.
NeoGenomics settles DOJ healthcare compliance probe for $9.8M, below $11.2M reserve
Filed July 20, 2026 · Period ending July 20, 2026 · ~1 min read
Key Changes
-
high
Company agreed to pay $9.8M plus interest to resolve DOJ investigation into consulting services provided to healthcare providers under its Laboratory Collaboration Initiative program, settling federal healthcare fraud and abuse compliance concerns.
Item 8.01 — Other Events verify on EDGAR → -
high
Settlement amount came in $1.4M below the $11.2M reserve previously accrued as of March 31, 2026, indicating the financial impact was within management's expectations.
Item 8.01 — Other Events verify on EDGAR → -
medium
NeoGenomics voluntarily disclosed the matter to the Office of Inspector General in November 2021 after conducting an internal investigation, and cooperated with the government investigation throughout.
Item 8.01 — Other Events verify on EDGAR → -
medium
Settlement resolves the investigation without admission of liability, allowing the company to close a legacy compliance matter and move forward with its oncology diagnostics business.
Exhibit 99.1 view on EDGAR →
Summary
NeoGenomics has settled a Department of Justice investigation into consulting services it provided to healthcare providers, agreeing to pay $9.8 million plus interest accruing from January 16, 2026. The investigation focused on whether certain consulting and service agreements under the company's Laboratory Collaboration Initiative program complied with federal healthcare laws relating to fraud, waste and abuse.
The company voluntarily disclosed the matter to the Office of Inspector General in November 2021 after conducting an internal investigation, demonstrating proactive compliance efforts. The settlement amount came in approximately $1.4 million below the $11.2 million reserve NeoGenomics had accrued as of March 31, 2026, suggesting management had appropriately estimated the potential liability.
The resolution closes without admission of wrongdoing, allowing the company to move past this legacy compliance issue. For investors, the settlement removes regulatory uncertainty that has hung over the company since the 2021 disclosure. The financial impact is contained and already reflected in prior quarters' financials, though the underlying conduct that triggered the investigation—consulting arrangements with referring providers—raises questions about the company's historical compliance practices in a heavily regulated industry.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice (“DOJ”) on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021.
NeoGenomics has settled a DOJ investigation into consulting services it provided to healthcare providers under its Laboratory Collaboration Initiative program. The company voluntarily disclosed the matter to the OIG in November 2021 and cooperated with the investigation. The settlement resolves the investigation without admission of liability.
Added in current filing · verify on EDGAR →
The Company has agreed to pay $9,813,260 plus interest at a rate of 4.250% per annum from January 16, 2026 to the United States o resolve the matter. The Company previously disclosed in its SEC filings that it had accrued a reserve of $11.2 million to cover potential damages and liabilities associated with the investigation.
NeoGenomics will pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026 to settle the matter. The company had previously accrued a reserve of $11.2 million for this investigation, meaning the actual settlement came in below the reserved amount by approximately $1.4 million before interest.
Added in current filing · view on EDGAR →
Tony Zook, Chief Executive Officer, commented, “We are pleased to resolve this legacy matter. The resolution of this voluntary disclosure will allow the Company to continue moving forward with its vision and commitment to advancing personalized cancer care.”
CEO Tony Zook characterized the settlement as resolving a legacy matter, allowing the company to move forward with its business strategy. The company frames the resolution as closing a chapter on a self-disclosed compliance issue.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021.
The company voluntarily conducted an internal investigation into certain consulting and service agreements' compliance with federal healthcare laws, including fraud, waste and abuse regulations. NeoGenomics voluntarily notified OIG-HHS of this investigation in November 2021, demonstrating proactive disclosure to regulators.
Event · Item 7.01 — Regulation FD Disclosure
NeoGenomics issued a press release on June 20, 2026 regarding a settlement agreement.
Added in current filing · verify on EDGAR →
On June 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in
The company disclosed that it issued a press release regarding a settlement agreement on June 20, 2026. The filing text appears incomplete and does not provide details about the nature of the settlement, the parties involved, or the financial terms. The truncated disclosure prevents assessment of the settlement's materiality or business impact.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 21, 2026 · How we verify